Unlocking Insights: Imaging and Biomarkers in Parkinson's (2023)

Dr. Jon Stoessl, head of neurology at the University of British Columbia, highlighted neuroimaging's role as a Parkinson's disease (PD) biomarker, stressing tailored therapies and early detection in high-risk individuals in this webinar. He covered diverse research advancements, including molecular imaging's use, challenges in correlating markers with improvements, and emerging fluid markers.

The webinar also discussed various diagnostic techniques, such as MRI, dopamine imaging, fluid biomarkers, genetic testing, and lifestyle impacts. It touched on interpreting test outcomes, the gut-Parkinson's link, and melatonin's potential for sleep disorders.

Additionally, challenges in studying and treating Parkinson's and related disorders were addressed, including therapy target issues, Alzheimer's progression, diagnostic limitations, gait abnormalities, diverse PD definitions, imaging's role in validation, levodopa's safety, and stem cell therapy progress.

**Disclaimer: These sessions are designed to provide general education and are not intended for individual advice and/or clinical care. The information conveyed in this recording was accurate at the time of presentation.**